Strive CEO: Digital lending price volatility is driven by leveraged liquidation events, not by underlying credit quality deterioration
Odaily reported that the Strive CEO posted on X, stating that today is the most challenging day in the history of digital credit. STRC rebounded sharply after trading as low as $82.50, and SATA also bounced back after falling from near par value to the low $90 range. What happened today was a leverage liquidation event, not a deterioration in underlying credit quality. Strive’s dividend reserves remain intact, the company is not under pressure, and still has the ability to fulfill its obligations and continue executing its strategy. The issuer's credit status remains solid, with the underlying credit situation largely unchanged from before today's volatility. Both STRC and SATA saw significant buying near the day’s lows, pushing prices back up. A liquidation event is not the same as a credit event; today’s price movements have not changed their confidence in the long-term opportunities of digital credit.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
